Telitacicept 
RemeGen
[' aa ', 'telitacicept', 'prednisone', 'valent ,(-prevalent)', 'emergent ']
novel and promising fusion protein of blys/april dual inhibitor #telitacicept in #sle phase 3, randomized, placebo-controlled 52-week study #eular2023 significantly higher sri-4 response rates lowered risk of flare/severe flare not increase the risk of infections 
MD, PhD candidate. Rheumatologist focused in #CardiovascularRisk #AutoimmuneDiseases #RheumatoidArthritis #Spondyloarthritis